公司简介
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid...
关联新闻
- Moderna stock rises 8%: can it continue its cancer vaccine success rally?
Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher pric...
- Moderna's AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
- Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.
2026 is the year of the cancer breakthrough, with innovations from Revolution Medicines and Moderna. "I'm almost tired of saying paradigm shift, but I haven't figured out a new phrase," one expert sai...
- Moderna (MRNA) Price Forecast: Bullish Pennant Points Toward Higher Targets
Moderna consolidates after a dramatic breakout, with a bullish pennant forming near resistance and offering a potential signal for another powerful advance.
- Why Moderna Stock's Cancer Vaccine Rally Sparked a Rare Sell Rating
Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.
- US FDA approves updated COVID vaccines for 2026-27 season
The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID vaccines, the companies said on Thursday, after an advisory panel recommended that the shot...
- Was Moderna Stock's 440% Surge Hiding In Plain Sight?
This article was written by Doug Nathman, with research by his team at Trefis.
- Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.
Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.